Literature DB >> 27308355

Targeting the sumoylation pathway in cancer stem cells.

Maria V Bogachek1, James P De Andrade1, Ronald J Weigel2.   

Abstract

Cancer stem cells (CSCs) represent a subset of tumor cells with tumor-initiating potential. We recently demonstrated that inhibition of the sumoylation pathway cleared the CSC population and repressed the outgrowth of basal breast cancer xenografts. Targeting the sumoylation pathway offers a novel treatment strategy for basal breast cancer.

Entities:  

Keywords:  CD44; SUMO; TFAP2A; basal breast cancer; cancer stem cells; epithelial-mesenchymal transition; sumoylation

Year:  2014        PMID： 27308355      PMCID： PMC4905063          DOI： 10.4161/23723548.2014.964624

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

Review 1.  Post-translational modification by the small ubiquitin-related modifier SUMO has big effects on transcription factor activity.

Authors:  Grace Gill
Journal:  Curr Opin Genet Dev       Date:  2003-04       Impact factor: 5.578

2.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 3.  SUMOylation in carcinogenesis.

Authors:  Kira Bettermann; Martin Benesch; Serge Weis; Johannes Haybaeck
Journal:  Cancer Lett       Date:  2011-11-02       Impact factor: 8.679

4.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Authors:  T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

5.  SUMO-mediated inhibition of glucocorticoid receptor synergistic activity depends on stable assembly at the promoter but not on DAXX.

Authors:  Sam R Holmstrom; Sergey Chupreta; Alex Yick-Lun So; Jorge A Iñiguez-Lluhí
Journal:  Mol Endocrinol       Date:  2008-06-18

6.  Sumoylation pathway is required to maintain the basal breast cancer subtype.

Authors:  Maria V Bogachek; Yizhen Chen; Mikhail V Kulak; George W Woodfield; Anthony R Cyr; Jung M Park; Philip M Spanheimer; Yingyue Li; Tiandao Li; Ronald J Weigel
Journal:  Cancer Cell       Date:  2014-05-15       Impact factor: 31.743

7.  Control of progesterone receptor transcriptional synergy by SUMOylation and deSUMOylation.

Authors:  Hany A Abdel-Hafiz; Kathryn B Horwitz
Journal:  BMC Mol Biol       Date:  2012-03-22       Impact factor: 2.946

Review 8.  Basal breast cancer: a complex and deadly molecular subtype.

Authors:  F Bertucci; P Finetti; D Birnbaum
Journal:  Curr Mol Med       Date:  2012-01       Impact factor: 2.222

9.  An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer.

Authors:  H E Lee; J H Kim; Y J Kim; S Y Choi; S-W Kim; E Kang; I Y Chung; I A Kim; E J Kim; Y Choi; H S Ryu; S Y Park
Journal:  Br J Cancer       Date:  2011-05-10       Impact factor: 7.640

10.  RUNX family members are covalently modified and regulated by PIAS1-mediated sumoylation.

Authors:  J-H Kim; J-W Jang; Y-S Lee; J-W Lee; X-Z Chi; Y-H Li; M-K Kim; D-M Kim; B-S Choi; J Kim; H-M Kim; A van Wijnen; Ily Park; S-C Bae
Journal:  Oncogenesis       Date:  2014-04-28       Impact factor: 7.485
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.